Wells Fargo & Company Iovance Biotherapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 496,396 shares of IOVA stock, worth $5.13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
496,396
Previous 367,787
34.97%
Holding current value
$5.13 Million
Previous $5.45 Million
26.95%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding IOVA
# of Institutions
323Shares Held
239MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$268 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$268 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$248 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$219 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$131 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.63B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...